Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a sell rating to a hold rating in a report released on Tuesday.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, ValuEngine upgraded shares of Ekso Bionics from a strong sell rating to a sell rating in a research note on Friday, November 17th.
Shares of Ekso Bionics (NASDAQ EKSO) traded down $0.07 during trading on Tuesday, hitting $1.95. 473,046 shares of the stock were exchanged, compared to its average volume of 1,047,263. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. Ekso Bionics has a twelve month low of $0.99 and a twelve month high of $4.77. The firm has a market capitalization of $121.01, a PE ratio of -2.10 and a beta of 2.01.
Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.05). Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%. The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.40 million. equities research analysts anticipate that Ekso Bionics will post -0.81 EPS for the current year.
In other news, insider Russ Angold sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total value of $175,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.32% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Carl Domino Inc increased its position in Ekso Bionics by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock worth $224,000 after acquiring an additional 102,734 shares during the period. Intellectus Partners LLC increased its position in Ekso Bionics by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after acquiring an additional 5,294 shares during the period. National Planning Corp increased its position in Ekso Bionics by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock worth $620,000 after acquiring an additional 286,492 shares during the period. Finally, Vanguard Group Inc. increased its position in Ekso Bionics by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after acquiring an additional 176,197 shares during the period. 6.22% of the stock is currently owned by institutional investors and hedge funds.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.